

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10634114
	Filing Date		2003-08-04
	First Named Inventor	Gary D. Glick	
	Art Unit	1618	
	Examiner Name	Ebrahim	
	Attorney Docket Number	UM-08192	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6605593		2003-08-12	Naicker	
	2	6613739		2003-09-02	Naicker	
	3	4916138		1990-04-10	Ueda	
	4	4929611		1990-05-29	Okuhara	
	5	4894366		1990-01-16	Okuhara	
	6	7175953		2007-02-13	Licha	
	7	5677282		1997-10-14	Oleksyszyn	
	8	RE30293		1980-06-03	Bub	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim
Attorney Docket Number	UM-08192

U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T <sup>5</sup>
	1	OTTO, Michael W., Ph.D., et al., "Benzodiazepine Use, Cognitive Impairment, and Cognitive-Behavioral Therapy for Anxiety Disorders: Issues in the Treatment of a Patient in Need," J. Clin. Psychiatry, 2005, 66 (supp 2).						<input type="checkbox"/>
	2	YOSHI, M., et al., (2005) Nippon Yakurigaku Zasshi 125(1):33-36 (English Abstract attached)						<input type="checkbox"/>
	3	YASUDA, K., (2004) Nippon Rinsho. 62 Suppl. 12:360-363. Abstract not available.						<input type="checkbox"/>
	4	DECAUDIN, Didier, "Peripheral benzodiazepine receptor and its clinical targeting," Anti-Cancer Drugs, 2004, Vol. 15, No. 8						<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10634114
Filing Date		2003-08-04
First Named Inventor	Gary D. Glick	
Art Unit		1618
Examiner Name	Ebrahim	
Attorney Docket Number		UM-08192

5	BONNOT, O., et al., "Exposition in utero au lorazepam et atresie anale: signal epidemiologique," (2003) Encephale. 29 (6):553-559	<input type="checkbox"/>
6	LACAPERE, Jean-Jacques, Vassilios Papadopoulos, "Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis," Steroids, 68 (2003) 569-585	<input type="checkbox"/>
7	GALIEGUE, S., et al., "The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target," (2003) Curr. Med. Chem (10(16):1563-1572	<input type="checkbox"/>
8	PAPADOPOULOU, V. (2003), Lecture: Peripheral benzodiazepine receptor: structure and function in health and disease," Ann. Pharm. Fr. 61(1):30-50	<input type="checkbox"/>
9	GOETHALS, Ingeborg, et al., "Is central benzodiazepine receptor imaging useful for the identification of epileptogenic foci in localization-related epilepsies?" European Journal of Nuclear Medicine and Molecular Imaging Vol. 30, No. 2, February 2003	<input type="checkbox"/>
10	CASTEDO, Marian, et al., "Mitochondrial Apoptosis and the Peripheral Benzodiazepine Receptor: a Novel Target for Viral and Pharmacological Manipulation," The Journal of Experimental Medicine, Vol. 196, No. 9, November 4, 2002	<input type="checkbox"/>
11	BUFFETT-JERROTT S.E. et al., "Cognitive and Sedative Effects of Benzodiazepine Use," Current Pharmaceutical Design, 2002, 8, 45-48	<input type="checkbox"/>
12	SMYTH, W.F., et al. (1998), "A critical evaluation of the application of capillary electrophoresis to the detection and determination of 1,4-benzodiazepine tranquilizers in formulations and body materials," Electrophoresis 19 (16-17):2870-2882	<input type="checkbox"/>
13	YOSHII, M., et al. (1998) Nihon Shinkeo Seishin Yakurigaku Zasshi, 18(2):49-54	<input type="checkbox"/>
14	VARANI, et al., (1994), "All-trans Retinoic Acid (RA) Stimulates Events in Organ-cultured Human Skin that Underlie Repair," J. Clin. Invest., 94:1747-1753	<input type="checkbox"/>
15	GRIFFITH, C.E., "Editorial Comment: Ascomycin: an advance in the management of atopic dermatitis," Br. J. Dermatol., 2001, April; 144(4):679-81	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim
Attorney Docket Number	UM-08192

16	STERN, R.S. (1995), "Epidemiology of Psoriasis," Dermatologic Clinics, 13:717-722	<input type="checkbox"/>
17	FRY, L (1988), "Psoriasis," Brit. J. Dermatol., 119:445-461	<input type="checkbox"/>
18	KRUEGER GC, et al., (1984), "Psoriasis," J. Am. Acad. Dermatol., 11:937-947	<input type="checkbox"/>
19	VARANI, J., et al. (2001), "Heparin-Binding Epidermal-Growth-Factor-Like Growth Factor Activation of Keratinocyte ErbB...", J. Invest. Dermatol., 117:1335-1341	<input type="checkbox"/>
20	VARANI, J., et al., "A Novel Benzodiazepine Selectively Inhibits Keratinocyte Proliferation...", The Journal of Pharmacology and Experimental Therapeutics, 2005, Vol. 313, No. 1, pp. 56-63.	<input type="checkbox"/>
21	International Search Report and Written Opinion, PCT/US2008/082629, mailed June 1, 2009	<input type="checkbox"/>
22	BISAHA, S.N., et al., "A switch in enantiomer preference between mitochondrial F1F0-ATPase chemotypes, Bioorganic & Medicinal Chemistry Letters, 2005 15(11), pp. 2749-2751.	<input type="checkbox"/>
23	International Search Report and Written Opinion dated March 27, 2009, PCT/US2008/076021	<input type="checkbox"/>
24	EP Supplementary Search Report, EP Application No. 02794914.8 dated November 6, 2008	<input type="checkbox"/>
25	EP Patent Application No. 05 80 4417 Supplementary European Search Report dated March 26, 2009	<input type="checkbox"/>
26	ALGARRA, et al., "Application of the Photo-Fries Rearrangement of Aryl N-Chloroacetylanthranylates as Key Step in the ...", Heterocycles, vol. 36 1993, pp. 2335-2344	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim
Attorney Docket Number	UM-08192

27	EP Patent Application No. 06 717616 Supplementary Search Report dated March 26, 2009	<input type="checkbox"/>
28	LEVITZKI, Alexander, "Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents," Pharmacol. Ther. Vol. 82, Nos. 2-3, pp. 231-239 (1999)	<input type="checkbox"/>
29	SANCHEZ, et al., "Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2" Proc Natl Acad Sci U S A (1995, June 6) 92(12) 5287-5291	<input type="checkbox"/>
30	JI YANG, et al., "Prevention of Apoptosis by BCL-2; Release of Cytochrome c from Mitochondria Blocked" Science Vol. 275, no. 5303, pp. 1129	<input type="checkbox"/>
31	PRINDULL, "Apoptosis in the embryo and tumorigenesis" European Journal of Cancer, Vol. 31, Issue 1 (1995) pp 116-123	<input type="checkbox"/>
32	Chinese Office Action , CN Patent Application No. 200580029827.4, dated April 17, 2009	<input type="checkbox"/>
33	LOWE, "Systemic treatment of severe psoriasis," The New England Journal of Medicine, 324 (5), February 7, 1991, pp. 333-334.	<input type="checkbox"/>
34	LAUPACIS, et al., "Cyclosporin A: a powerful immunosuppressant", CMA Journal, May 1, 1982, Vol. 126, pp. 1041-1046	<input type="checkbox"/>
35	LEE, et al., J. Org. Chem. 1999, 64, 3060-3065	<input type="checkbox"/>
36	SOLOMKO, et al., Chemistry of Heterocyclic Compounds, Vol. 11, No. 11, November 1975, pp. 1231-1248	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10634114
Filing Date	2003-08-04
First Named Inventor	Gary D. Glick
Art Unit	1618
Examiner Name	Ebrahim
Attorney Docket Number	UM-08192

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.